- Home
- LTH vs QGEN Comparison
LTH vs QGEN Comparison
Compare LTH & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTH | QGEN |
|---|---|---|
| Founded | 1992 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 9.0B |
| IPO Year | 2021 | 1998 |
Fundamental Metrics
Financial Performance| Metric | LTH | QGEN |
|---|---|---|
| Price | $40.55 | $41.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 16 |
| Target Price | ★ $56.07 | $46.27 |
| AVG Volume (30 Days) | ★ 2.5M | 1.6M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 6.31% |
| EPS Growth | ★ 124.32 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $2,995,255,000.00 | N/A |
| Revenue This Year | $12.51 | $2.19 |
| Revenue Next Year | $11.97 | $5.06 |
| P/E Ratio | $48.27 | ★ $24.01 |
| Revenue Growth | ★ 14.28 | N/A |
| 52 Week Low | $24.14 | $32.53 |
| 52 Week High | $47.24 | $57.82 |
Technical Indicators
Market Signals| Indicator | LTH | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 39.97 | 51.31 |
| Support Level | $25.67 | $41.34 |
| Resistance Level | $41.79 | $44.72 |
| Average True Range (ATR) | 1.42 | 0.92 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 55.97 | 52.18 |
Price Performance
Historical ComparisonAbout LTH Life Time Group Holdings Inc.
Life Time Group Holdings Inc is a lifestyle and leisure brand offering health, fitness, and wellness experiences to a community. It is engaged in designing, building, and operating distinctive and large, multi-use sports and athletic, professional fitness, family recreation, and spa centers in a resort-like environment, principally in residential locations of metropolitan areas in the United States and Canada.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).